Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Cash from Operations (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Cash from Operations data on record, last reported at 28498000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 342.35% year-over-year to 28498000.0; the TTM value through Sep 2025 reached 76156000.0, up 33.39%, while the annual FY2024 figure was 67139000.0, 70.14% up from the prior year.
  • Cash from Operations reached 28498000.0 in Q3 2025 per SGMO's latest filing, down from 18158000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 11759000.0 in Q3 2024 and bottomed at 68550000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 43245473.68, with a median of 52567000.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: tumbled 1127.33% in 2021, then skyrocketed 124.86% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 52714000.0 in 2021, then decreased by 8.22% to 57049000.0 in 2022, then grew by 11.41% to 50538000.0 in 2023, then skyrocketed by 93.37% to 3351000.0 in 2024, then tumbled by 750.43% to 28498000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 28498000.0 in Q3 2025, 18158000.0 in Q2 2025, and 26149000.0 in Q1 2025.